Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Biological activity of modified and exchanged 2-amino-5-nitrothiazole amide analogues of nitazoxanide.

Ballard TE, Wang X, Olekhnovich I, Koerner T, Seymour C, Hoffman PS, Macdonald TL.

Bioorg Med Chem Lett. 2010 Jun 15;20(12):3537-9. doi: 10.1016/j.bmcl.2010.04.126. Epub 2010 May 18.

2.

Antiparasitic drug nitazoxanide inhibits the pyruvate oxidoreductases of Helicobacter pylori, selected anaerobic bacteria and parasites, and Campylobacter jejuni.

Hoffman PS, Sisson G, Croxen MA, Welch K, Harman WD, Cremades N, Morash MG.

Antimicrob Agents Chemother. 2007 Mar;51(3):868-76. Epub 2006 Dec 11.

3.

Amixicile, a novel inhibitor of pyruvate: ferredoxin oxidoreductase, shows efficacy against Clostridium difficile in a mouse infection model.

Warren CA, van Opstal E, Ballard TE, Kennedy A, Wang X, Riggins M, Olekhnovich I, Warthan M, Kolling GL, Guerrant RL, Macdonald TL, Hoffman PS.

Antimicrob Agents Chemother. 2012 Aug;56(8):4103-11. doi: 10.1128/AAC.00360-12. Epub 2012 May 14.

4.

Synthesis and antimicrobial evaluation of nitazoxanide-based analogues: identification of selective and broad spectrum activity.

Ballard TE, Wang X, Olekhnovich I, Koerner T, Seymour C, Salamoun J, Warthan M, Hoffman PS, Macdonald TL.

ChemMedChem. 2011 Feb 7;6(2):362-77. doi: 10.1002/cmdc.201000475. Epub 2010 Dec 29.

5.

Preclinical studies of amixicile, a systemic therapeutic developed for treatment of Clostridium difficile infections that also shows efficacy against Helicobacter pylori.

Hoffman PS, Bruce AM, Olekhnovich I, Warren CA, Burgess SL, Hontecillas R, Viladomiu M, Bassaganya-Riera J, Guerrant RL, Macdonald TL.

Antimicrob Agents Chemother. 2014 Aug;58(8):4703-12. doi: 10.1128/AAC.03112-14. Epub 2014 Jun 2.

6.

Nitazoxanide, a nitrothiazolide antiparasitic drug, is an anti-Helicobacter pylori agent with anti-vacuolating toxin activity.

Yamamoto Y, Hakki A, Friedman H, Okubo S, Shimamura T, Hoffman PS, Rossignol J.

Chemotherapy. 1999 Jul-Aug;45(4):303-12.

PMID:
10394014
7.
8.

In vitro and in vivo activities of nitazoxanide against Clostridium difficile.

McVay CS, Rolfe RD.

Antimicrob Agents Chemother. 2000 Sep;44(9):2254-8.

9.
10.

Nitazoxanide Analogues as Antimicrobial Agents Against Nosocomial Pathogens.

Gau JS, Lin WP, Kuo LC, Hu MK.

Med Chem. 2016;12(6):544-52.

PMID:
26825066
11.

Enzymes associated with reductive activation and action of nitazoxanide, nitrofurans, and metronidazole in Helicobacter pylori.

Sisson G, Goodwin A, Raudonikiene A, Hughes NJ, Mukhopadhyay AK, Berg DE, Hoffman PS.

Antimicrob Agents Chemother. 2002 Jul;46(7):2116-23.

12.

Antiprotozoal Nitazoxanide Derivatives: Synthesis, Bioassays and QSAR Study Combined with Docking for Mechanistic Insight.

Scior T, Lozano-Aponte J, Ajmani S, Hernández-Montero E, Chávez-Silva F, Hernández-Núñez E, Moo-Puc R, Fraguela-Collar A, Navarrete-Vázquez G.

Curr Comput Aided Drug Des. 2015;11(1):21-31.

13.

Metronidazole-triazole conjugates: activity against Clostridium difficile and parasites.

Jarrad AM, Karoli T, Debnath A, Tay CY, Huang JX, Kaeslin G, Elliott AG, Miyamoto Y, Ramu S, Kavanagh AM, Zuegg J, Eckmann L, Blaskovich MA, Cooper MA.

Eur J Med Chem. 2015 Aug 28;101:96-102. doi: 10.1016/j.ejmech.2015.06.019. Epub 2015 Jun 18.

14.

Antibacterial and Solubility Optimization of Thiomuracin A.

LaMarche MJ, Leeds JA, Brewer J, Dean K, Ding J, Dzink-Fox J, Gamber G, Jain A, Kerrigan R, Krastel P, Lee K, Lombardo F, McKenney D, Neckermann G, Osborne C, Palestrant D, Patane MA, Rann EM, Robinson Z, Schmitt E, Stams T, Tiamfook S, Yu D, Whitehead L.

J Med Chem. 2016 Jul 28;59(14):6920-8. doi: 10.1021/acs.jmedchem.6b00726. Epub 2016 Jul 12.

PMID:
27355833
15.

Antibacterial activity of rifaximin against Clostridium difficile, Campylobacter jejunii and Yersinia spp.

Mignini F, Falcioni E, Prenna M, Santacroce F, Ripa S.

J Chemother. 1989 Jul;1(4 Suppl):220-2. No abstract available.

PMID:
16312377
16.

Synthesis and biological evaluation of substituted 4-arylthiazol-2-amino derivatives as potent growth inhibitors of replicating Mycobacterium tuberculosis H₃₇Rv.

Roy KK, Singh S, Sharma SK, Srivastava R, Chaturvedi V, Saxena AK.

Bioorg Med Chem Lett. 2011 Sep 15;21(18):5589-93. doi: 10.1016/j.bmcl.2011.06.076. Epub 2011 Jul 2.

PMID:
21783364
17.

Anaerobic respiration: In vitro efficacy of Nitazoxanide against mitochondriate Acanthamoeba castellanii of the T4 genotype.

Aqeel Y, Siddiqui R, Farooq M, Khan NA.

Exp Parasitol. 2015 Oct;157:170-6. doi: 10.1016/j.exppara.2015.08.007. Epub 2015 Aug 19.

PMID:
26297676
18.

[Antagonistic activity of Lactobacillus bacteria strains against anaerobic gastrointestinal tract pathogens (Helicobacter pylori, Campylobacter coli, Campylobacter jejuni, Clostridium difficile)].

Strus M, Pakosz K, Gościniak H, Przondo-Mordarska A, Rozynek E, Pituch H, Meisel-Mikołajczyk F, Heczko PB.

Med Dosw Mikrobiol. 2001;53(2):133-42. Polish.

PMID:
11757422
19.

Synthesis and Antimicrobial Evaluation of Amixicile-Based Inhibitors of the Pyruvate-Ferredoxin Oxidoreductases of Anaerobic Bacteria and Epsilonproteobacteria.

Kennedy AJ, Bruce AM, Gineste C, Ballard TE, Olekhnovich IN, Macdonald TL, Hoffman PS.

Antimicrob Agents Chemother. 2016 Jun 20;60(7):3980-7. doi: 10.1128/AAC.00670-16. Print 2016 Jul.

20.

Narrow-spectrum inhibitors of Campylobacter jejuni flagellar expression and growth.

Johnson JG, Yuhas C, McQuade TJ, Larsen MJ, DiRita VJ.

Antimicrob Agents Chemother. 2015 Jul;59(7):3880-6. doi: 10.1128/AAC.04926-14. Epub 2015 Apr 13.

Supplemental Content

Support Center